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Abstract
Introduction
• ASCVD is the most common cause of death worldwide. In 2010, 
ASCVD accounted for approximately 16 million deaths, 40% of deaths 
in the developed world (Kasper et al., 2015).  
• Researchers and clinicians divide their treatment strategies in to 2 
categories; primary prevention and secondary prevention. Primary 
prevention seeks to prevent new-onset ASCVD, while secondary 
prevention extends to all other patients with already established 
ASCVD. 
• Lowering LDL-C levels to set target goals using statin drugs is the 
standard treatment regime. 
• Early in the 21st century researchers started to question if LDL-C was 
actually the biomarker that best predicted ASCVD.  ApoB and non-
HDL-C were lipid biomarker that received much attention and 
research.
• One ApoB molecule is attached to each VLDL, IDL, and LDL. 
Measuring apoB directly measures the number of all 3 atherogenic lipid 
particles. Its measurement requires fasting, a high cost, and is not 
standardized.
• Non-HDL-C is calculated by subtracting HDL-C from total cholesterol. 
Like apoB, non-HDL-C measurement is a way to determine combined 
levels of VLDL, IDL, and LDL
Research Questions





• The ACC/AHA Guideline on the Treatment of Blood Cholesterol to 
Reduce Atherosclerotic Cardiovascular Risk in Adults, by Stone et al. 
(2013), is one of the most widely used guideline by clinicians in the 
U.S. The most recent report published in 2013 brought about 
departure from past reports and a different approach than guidelines 
from other cardiovascular associations. These guidelines were the first 
to exclude treatment goals for LDL-C. Rather than using the 
concentration of lipids in the blood as a treatment goal, the ACC/AHA 
guidelines use the intensity of statin therapy as the goal of treatment.
• These new guidelines, and the absence of cholesterol targets, started a 
debate amongst clinicians and researchers.  Guidelines by the 
International Atherosclerosis Society (Expert Dyslipidemia Panel of the 
International Atherosclerosis Society Panel members, 2014), the 
National Lipid Association (Jacobson et al., 2015), and previous ATP 
guidelines all included LDL-C treatment goals. 
Lipid Biomarkers
• Up until recently all the attention has been paid to LDL-C, so-called 
‘bad cholesterol’. All previous guidelines used the concentration of 
LDL-C in the blood to determine the type of intervention and assess for 
successful treatment. LDL-C is now firmly entrenched in the minds of 
patients and clinicians alike as the primary marker for cardiovascular 
health.  
• Boekholdt et al. (2012) found that non-HDL-C is more strongly 
associated with cardiovascular events than LDL-C and apoB.
• Research by Pischon et al. (2005) and Sniderman et al. (2011) found 
that apoB was the superior lipid biomarker, but that non-HDL-C was 
also more strongly correlated with CHD that LDL-C.
• Lowering low-density lipoprotein cholesterol (LDL-C) concentration in 
the population has been a goal of researchers and clinicians to prevent 
atherosclerotic cardiovascular disease (ASCVD). 
• Controversy surrounds using [LDL-C] as the primary lipid biomarker to 
evaluate the risk of cardiovascular events. An article search dating back 
to 2005 of PubMed and The Cochran Library was conducted. 
• The purpose of this investigation was to determine if LDL-C should be 
the primary lipid biomarker used to determine ASCVD treatment and 
prevention. This investigation researched other lipid biomarkers and 
targets to determine clinical relevance and if the level of those markers 
more accurately represents ASCVD in adults 21-75 years of age not 
afflicted by other chronic diseases. 
• It was found that both non-high-density lipoprotein cholesterol (non-
HDL-C) and apolipoprotein B (apoB) both better represent ASCVD risk 
than LDL-C, with apoB being superior to non-HDL-C. 
• What are the current guidelines for ASCVD treatment and prevention in 
adults 21-75 years of age?  
• In the rural primary care setting, where state-of-the-art laboratory 
equipment is unavailable, the use of which lipid biomarker is most 
efficacious in assessing ASCVD risk in male and female adults 21-75 
years of age?
Lipid Guidelines
• In 2013 guidelines by the American College of Cardiology and 
American Heart Association, by Stone et al. (2013) were released. 
These guidelines brought about a departure from the previous 
guidelines, eliminating goals for LDL-C. Instead of LDL-C therapeutic 
goals, on the basis of a large consistent body of evidence, 4 major statin 
benefit groups were identified for whom the ASCVD risk reduction 
clearly outweighs the risk of adverse events.
1) Secondary prevention in individuals with clinical ASCVD
2) Primary prevention in individuals with primary elevations of LDL-C 
≥ 190 mg/dL
3) Primary prevention in individuals with diabetes 40-75 years of age 
who have LDL-C 70-189 mg/dL,
4) Primary prevention in individuals without diabetes and with 
estimated 10-year ASCVD risk ≥ 7.5%, 40 to 75 years of age with 
LDL-C 70-189 mg/dL (Stone et al., 2013). 
• Two other prominent guidelines, from the International Atherosclerosis 
Society (IAS) and the National Lipid Association (NLA), each use LDL-C 
concentration levels to determine successful pharmacological 
prevention of ASCVD. However, because evidence shows that VLDL is 
atherogenic like LDL, both guidelines also contain an additionally 
recommended goal for Non-HDL-C. 
Lipoprotein Physiology
• Plasma lipoproteins are divided into five major classes based on their 
relative density: chylomicrons, very-low-density lipoproteins (VLDLs), 
intermediate-density lipoproteins (IDLs), low-density lipoproteins 
(LDLs), and high-density lipoproteins (HDLs).
Lipid Biomarkers
• LDL-C has been the mainstay biomarker and pharmacologic target to 
prevent ASCVD.  However, new research has provided evidence that 
other lipid biomarkers better represent the risk of developing ASCVD.
• A meta-analysis conducted by Boekholdt et al. (2012)  compared lipid 
biomarker levels in patients treated with statin medications with risk of 
cardiovascular events. The adjusted hazard ratios (HRs) for major CV 
events per 1-SD increase were 1.13 (95% CI 1.10-1.17) for LDL-C, 1.16 
(95% CI 1.12-1.19) for non-HDL-C, and 1.14 (95% CI 1.11-1.18) for 
apoB. These HRs were significantly higher for non-HDL-C that LDL-C 
(P=0.002) and apoB (P=0.02). This data led the authors to conclude 
“that among statin treated patients, non-HDL-C had a stronger 
association with risk of major cardiovascular events than LDL-C and 
apolipoprotein B” (Boekholdt et al., 2012, p. 1307). 
• A case-control study by Pischon et al. (2005), compared apoB, non–
HDL-C, LDL-C, and other lipid markers as predictors of coronary heart 
disease. After adjustment for matching factors, the relative risk of CHD 
in the highest quintile compared with the lowest quintile was 2.76 
(95% confidence interval [CI], 1.66 to 4.58) for non–HDL-C, 3.01 (95% 
CI, 1.81 to 5.00) for apoB, 1.81 (95% CI, 1.12 to 2.93) for LDL-C, 0.31 
(95% CI, 0.18 to 0.52) for HDL-C, 2.41 (95% CI, 1.43 to 4.07). The 
authors concluded “that non–HDL-C was more strongly correlated with 
CHD than LDL-C”, but that “apoB showed the strongest association 
with risk of CHD” and “apoB was associated with increased risk of 
CHD even after adjustment for LDL-C or non–HDL-C” (Pischon et al., 
2005).
• Sniderman et al. (2011) attempted to identify all “published 
epidemiological studies that contained estimates of the relative risks of 
non-HDL-C and apoB of fatal or nonfatal ischemic cardiovascular 
events” (p. 338).  The authors reported that apoB was the most potent 
marker of cardiovascular risk (RRR, 1.43; 95% CI, 1.35 to 1.51), LDL-C 
was the least (RRR, 1.25; 95% CI, 1.18 to 1.33), and non-HDL-C was 
intermediate (RRR, 1.34; 95% CI, 1.24 to 1.44).
Lipid Guidelines
• Treatment goals suggested by the NLA and IAS facilitate effective 
communication between the patient and clinician
• Treatment goals provide an easily understandable means to discuss 
progress towards effective therapy. This will maximize long-term 
adherence by the patient to the treatment strategy.
Lipid Biomarkers
• Non-HDL-C is the most efficacious lipid biomarker to assess risk of 
ASCVD and to evaluate successful treatment in rural primary care 
medicine.  
• Non-HDL-C simplifies results for both the clinician and the patient, is 
universally available, has low cost, does not requires fasting, and has 
been proven by research to be efficacious. 
• Non-HDL-C does not require addition laboratory equipment or studies 
besides the already standardized lipid panel. Non-HDL-C testing is 
simpler, calculated as the difference of 2 stable and easily measured 
parameters, total cholesterol and HDL-C. 
• I wish to express my most sincere gratitude and appreciation to Dr. 
Vikki McCleary, LRD, PhD for her guidance, patience, and 
encouragement throughout the development of this project. Her 
support was instrumental to the completion of this project and to my 
success as a graduate student at the University of North Dakota. 
Statement of the Problem
• With so many different lipid biomarkers used to evaluate ASCVD risk, 
and multiple treatment and prevention guidelines available, it is 
challenging for a primary care provider to select the most efficacious 
and cost-effective treatment plan.
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